Innoviva, Inc. INVA
We take great care to ensure that the data presented and summarized in this overview for Innoviva, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding INVA
View all-
Black Rock Inc. New York, NY9.63MShares$182 Million0.0% of portfolio
-
Sarissa Capital Management LP Greenwich, CT7.28MShares$138 Million34.93% of portfolio
-
Franklin Resources Inc San Mateo, CA6.75MShares$128 Million0.04% of portfolio
-
Putnam Investments LLC Boston, MA6.27MShares$119 Million0.14% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.23MShares$118 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX4.69MShares$88.9 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny4.33MShares$82.1 Million0.13% of portfolio
-
Pacer Advisors, Inc. Malvern, PA2.81MShares$53.3 Million0.13% of portfolio
-
State Street Corp Boston, MA2.45MShares$46.4 Million0.0% of portfolio
-
Westfield Capital Management CO LP Boston, MA1.99MShares$37.8 Million0.18% of portfolio
Latest Institutional Activity in INVA
Top Purchases
Top Sells
About INVA
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Insider Transactions at INVA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 20
2024
|
Marianne Zhen Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
975
-2.09%
|
$17,550
$18.49 P/Share
|
|
Jun 17
2024
|
Derek A Small Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,923
+37.53%
|
-
|
|
Jun 17
2024
|
Sapna Srivastava Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,923
+24.0%
|
-
|
|
Jun 17
2024
|
Jules Haimovitz Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,923
+9.62%
|
-
|
|
Jun 17
2024
|
Kostas D Odysseas Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,923
+10.2%
|
-
|
|
Jun 17
2024
|
Sarah J. Schlesinger Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,923
+10.5%
|
-
|
|
Jun 17
2024
|
Mark Di Paolo Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,923
+10.5%
|
-
|
|
May 20
2024
|
Matthew Ronsheim |
SELL
Payment of exercise price or tax liability
|
Direct |
268
-0.66%
|
$4,288
$16.13 P/Share
|
|
May 20
2024
|
Marianne Zhen Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
976
-2.05%
|
$15,616
$16.13 P/Share
|
|
Mar 05
2024
|
Stephen Basso Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,096
+50.0%
|
$169,344
$14.88 P/Share
|
|
Mar 05
2024
|
Marianne Zhen Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,752
+18.44%
|
$150,528
$14.88 P/Share
|
|
Mar 05
2024
|
Matthew Ronsheim |
BUY
Grant, award, or other acquisition
|
Direct |
12,768
+23.84%
|
$178,752
$14.88 P/Share
|
|
Feb 20
2024
|
Marianne Zhen Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,862
-7.21%
|
$42,930
$15.8 P/Share
|
|
Feb 20
2024
|
Matthew Ronsheim |
SELL
Payment of exercise price or tax liability
|
Direct |
807
-2.8%
|
$12,105
$15.8 P/Share
|
|
Jan 18
2024
|
Matthew Ronsheim |
SELL
Payment of exercise price or tax liability
|
Direct |
1,600
-5.26%
|
$25,600
$16.05 P/Share
|
|
Nov 20
2023
|
Marianne Zhen Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
784
-1.94%
|
$10,192
$13.62 P/Share
|
|
Nov 15
2023
|
Marianne Zhen Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
302
+0.74%
|
-
|
|
Nov 15
2023
|
Marianne Zhen Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
10,994
-11.39%
|
$142,922
$13.99 P/Share
|
|
Aug 18
2023
|
Marianne Zhen Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
785
-1.51%
|
$10,205
$13.64 P/Share
|
|
Jun 15
2023
|
Alexander J Denner |
BUY
Open market or private purchase
|
Indirect |
62,000
+0.84%
|
$806,000
$13.13 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 119K shares |
|---|
| Payment of exercise price or tax liability | 8.27K shares |
|---|---|
| Open market or private sale | 11K shares |